ArticleInternational journal of clinical and experimental pathology2018
PI3K expression predicts overall survival in lung adenocarcinoma.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPhosphoinositide 3-kinase (PI3K)/phosphorylated PI3K (p-PI3K) is considered a hallmark in tumor initiation and progression, but its prognostic value in non-small cell lung cancer (NSCLC) remains controversial.
methodsIn the present study, we included 118 NSCLC tissue samples and 13 adjacent normal lung tissue specimens. Immunohistochemical staining was applied to test PI3K/p-PI3K expression. Pearson Chi-squared test and Kaplan-Meier curve were conducted to analyze its correlation with both clinicopathological features and prognosis in NSCLC patients.
resultsPI3K/p-PI3K expression in lung cancer tissue differed significantly from that of normal lung tissue (P < 0.001). M stage was significantly correlated to PI3K expression (P = 0.037), but no significant association was found between p-PI3K expression and clinical characteristics. Neither PI3K nor p-PI3K were correlated to overall survival of NSCLC patients (P = 0.105 and P = 0.190, respectively). However, it was found in subgroup analysis that lung adenocarcinoma patients with positive PI3K expression had a favorable survival (P = 0.043). Notably, this correlation was determined invalid in subsequent multivariate analysis (P = 0.052).
conclusionsPI3K could predict the overall survival of lung adenocarcinoma patients, but failed to be an independent prognostic predictor.
Indexed as
Identifiers
31949564PMC6962901W3027891636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.